Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
LEGUBETI (ACETYLCYSTEINE LYSINE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
LEGUBETI
NDA
Get alerts
ACETYLCYSTEINE LYSINE | N215040 | GALEPHAR PHARMACEUTICAL RESEARCH INC
2 strengths
0 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
0 unique patents, 1 exclusivity by expiration date
All strengths
EQ 500MG BASE/PACKET
EQ 2.5GM BASE/PACKET
Today
Exclusivity
2027
Today
NP
Feb. 13, 2027
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 500MG BASE/PACKET
RLD
0 patents
1 exclusivity
▴
FOR SOLUTION;ORAL | Approved: Feb 13, 2024
Exclusivities (1)
Code
Date
Status
NP
Feb 13, 2027
< 1 year
#002 — EQ 2.5GM BASE/PACKET
RLD
0 patents
1 exclusivity
▾
FOR SOLUTION;ORAL | Approved: Feb 13, 2024